Answers are grounded in this paper and cite their sources.
Identifies CD30 as a crucial cytokine receptor for diagnosing non-Hodgkin's lymphomas, particularly ALCL, suggesting its potential in immunotherapy.
THE INITIAL description of the Ki-l monoclonal antibody (MoAb) in 1982,' there has been an overwhelming flood of information concerning the Hodgkm's disease @)associated molecule CD30. In a diagnostic point of view, the Ki-l antibody enabled in 1985' the identification of a new category of non-Hodgkn's lymphomas designated as Ki"D30 anaplastic large cell lymphoma (ALCL).'
No takes yet. Share an insight, caveat, or question.
Falini et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: